J.W. Cole Advisors, Inc. Acadia Pharmaceuticals Inc Transaction History
J.W. Cole Advisors, Inc.
- $5.04 Billion
- Q3 2025
A detailed history of J.W. Cole Advisors, Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, J.W. Cole Advisors, Inc. holds 20,131 shares of ACAD stock, worth $439,862. This represents 0.01% of its overall portfolio holdings.
Number of Shares
20,131
Previous 19,981
0.75%
Holding current value
$439,862
Previous $430,000
0.23%
% of portfolio
0.01%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding ACAD
# of Institutions
354Shares Held
164MCall Options Held
811KPut Options Held
334K-
Baker Bros. Advisors LP New York, NY42.9MShares$937 Million9.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.3MShares$334 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$264 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY9MShares$197 Million2.98% of portfolio
-
State Street Corp Boston, MA6.18MShares$135 Million0.01% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.54B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...